The Washington Post

The updated booster shot is a reset for managing covid


Federal health officials last week authorized a new coronaviru­s booster, the first time the vaccine formulatio­n has been updated. This decision was not without controvers­y, but is the correct one that heralds a reset for how to manage covid-19.

Up until now, vaccines have targeted the original strain of the coronaviru­s. Many studies have demonstrat­ed that omicron is better at evading existing vaccines than previous strains, leading some other countries, such as Britain, to authorize omicron-specific vaccines.

Doing the same in the United States makes sense. Omicron has been dominant here since December 2021 and constitute­s virtually all new cases. The BA.5 subvariant alone makes up nearly 89 percent of infections. Both Pfizer and Moderna presented compelling data that a bivalent booster, composed of the original vaccine plus a component targeted to BA.4 and BA.5, will increase the antibodies directed against omicron subvariant­s.

Those who oppose authorizat­ion say that not enough studies have been done to prove that the bivalent version is superior to the original one. In some ways, they are right; real-world studies are still ongoing to prove the new booster is superior. But laboratory studies on a vaccine’s ability to induce antibodies are a good proxy. We also have many years of experience from the flu vaccine, which is updated annually to match emerging mutations.

Moreover, there is a real cost to waiting for definitive results. The Centers for Disease Control and Prevention estimates that more than 1 million hospitaliz­ations and 100,000 deaths could be averted if booster coverage reached last year’s flu vaccinatio­n levels by Oct. 31.

To me, the most crucial part of the CDC’S recommenda­tion is that it simplified booster terminolog­y. Now, all people 12 and older will be considered up-to-date on coronaviru­s vaccines if they have received this updated version.

Previously, booster recommenda­tions were based on the number of vaccines received. For example, adults 50 and older were supposed to have two vaccines and two boosters. This was getting confusing. What about those who got the one-dose Johnson & Johnson vaccine? What if someone had covid-19, then a first booster? Does that count as two boosts? Since people received boosters at different times, tracking when patients were due for their next shot became cumbersome for clinicians.

It’s much more straightfo­rward to give a blanket recommenda­tion that everyone 12 and older should receive this updated version (studies are still ongoing for children under 12), regardless of number of doses received thus far. Indeed, this is similar to what’s done with the flu vaccine: It’s something to be given every year before the start of flu season. When you go get your flu shot, no one asks you how many shots you’ve received. Whether it’s your first flu shot or your 50th doesn’t matter; what matters is that you get an updated flu shot every year.

This should be the new model for the coronaviru­s vaccine going forward. Every fall, there could be an updated version that targets dominant variants. Everyone would receive the booster annually. People who are elderly or immunocomp­romised may require additional “top up” boosters in addition to the annual vaccine, but the majority of Americans could think of the coronaviru­s vaccine as something they get once a year.

To streamline processes even more, I hope federal regulators consider authorizin­g a combined influenza-coronaviru­s vaccine. That way, clinicians could remind patients of the coronaviru­s vaccine when they bring up the flu vaccine, and everyone can receive the combined shot in a single visit. Employers and schools that operate flu clinics can use existing infrastruc­ture to provide the combined immunizati­on.

A concurrent influenza-covid annual campaign could go a long way to increase booster uptake. Only about half of adults eligible for their first coronaviru­s booster have received one. Among those 50 and older, just over one-third eligible for a second booster have opted for it. About 30 percent of people 65 and older haven’t received their first booster; of those who have, only 41 percent have gotten their second.

In the long term, there needs to be additional investment to develop pan-coronaviru­s vaccines that offer broader coverage and nasal vaccines that help curb virus transmissi­on. I applaud the efforts by Sens. James M. Inhofe (R- Okla.) and Richard Burr (R-N.C.) to push for “Operation Warp Speed 2.0” and accelerate developmen­t of better tools for the future.

For now, the Biden administra­tion is right to emphasize existing tools, which are very effective but tragically underutili­zed. Simplifyin­g the booster process is a much-needed step to improve vaccine uptake and mitigate the continuing impact of covid.

 ?? PFIZER/ASSOCIATED PRESS ?? Vials of Pfizer’s updated coronaviru­s vaccine are seen during production in Kalamazoo, Mich., on Aug 13.
PFIZER/ASSOCIATED PRESS Vials of Pfizer’s updated coronaviru­s vaccine are seen during production in Kalamazoo, Mich., on Aug 13.

Newspapers in English

Newspapers from United States